Back to Journals » Therapeutics and Clinical Risk Management » Volume 15

Emerging Treatment Options For Cancer-Associated Cachexia: A Literature Review

Authors Naito T

Received 29 August 2019

Accepted for publication 8 October 2019

Published 29 October 2019 Volume 2019:15 Pages 1253—1266

DOI https://doi.org/10.2147/TCRM.S196802

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Nicola Ludin

Peer reviewer comments 2

Editor who approved publication: Professor Deyun Wang


Video abstract presented by Tateaki Naito.

Views: 151

Tateaki Naito

Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan

Correspondence: Tateaki Naito
Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto District, Shizuoka 411-0934, Japan
Tel +81-55-989-5222
Fax +81-55-989-5783
Email t.naito@scchr.jp

Abstract: Cachexia is a disease that has been recognized since antiquity; however, research in this area has recently increased. Promising new agents, including anamorelin hydrochloride, have been tested in large randomized controlled studies, and multidrug as well as multimodal approaches have been proposed as having the potential to improve outcomes in patients with cancer cachexia. However, standard treatment remains elusive. This review summarizes the current literature on treatment of cancer-associated cachexia, showing that there are challenges associated with conducting clinical trials in such patients. First, poor recruitment, retention, and compliance among cachectic patients cause research delays. Second, the lack of consensus regarding clinically meaningful endpoints impedes standardization of study designs and results. Further consideration is needed to identify the most suitable study design and endpoints, which can lead to the development of pharmacological and nonpharmacological interventions that improve patients’ prognosis and outcomes.

Keywords: cancer cachexia, physical function, anamorelin, multimodal intervention

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]